IngredientesAcemannan is a β-(1,4)-acetylated soluble polymannose and the major bioactive polysaccharide of Aloe vera. The Carrington Laboratory in the United States named the acetylated mannan extracted and purified from Aloe barbadensis Mill. "acemannan." It is a highly acetylated mannan linked by β-(1,4) glycosidic bonds, which has undergone a series of extraction and purification processes for experimental and clinical research.
Acemannan, commercially known as Carrisyn™, is a linear polysaccharide composed of (1,4)-linked mannosyl residues, with C2 or C3 acetylated and some side chains of mainly galactose attached to C6. A more detailed structural analysis reveals that it contains a single-chain backbone consisting of β-(1→4) mannose, with β-(1→4) glucose integrated into the backbone, and α-(1→6) galactose branching out from the backbone.
Previous studies have reported varying ratios of glucose to mannose repeating units, such as 1:6, 1:15, and 1:22, which can be attributed to variations in aloe subspecies and differences in sample processing methods. The structure of acemannan consists of a polydispersed β-(1,4)-linked acetylated mannan interspersed with O-acetyl groups. The degree of acetylation is about 0.91 acetyl groups per monomer. The ratio between mannose and galactose is about 20:1.
Aloe polysaccharides are long polymers with an average molecular weight exceeding 1 million Daltons. Heating mainly increased the average molecular weight of polysaccharides from 45 kDa to 81 kDa, which may be mainly due to structural modifications such as deacetylation and losses of galactose-rich side-chains from the mannose backbones. Related studies show that the losses of galactosyl residues and deacetylation would result in mannose-rich chains of higher molecular weight. The distribution of acetyl groups and galactosyl units in the main chain can have a significant effect on the physical and biological characteristics of acemannan.
Acemannan, a mannose-containing polysaccharide, has been reported as the main active substance present in the Aloe vera filet (inner gel). The polysaccharide detected in the filet and in the gel fractions corresponds to a storage polysaccharide located within the protoplast of the parenchymatous cells. Its structural and compositional features correspond to the active polysaccharide known as acemannan. The fact that acemannan is a reserve polysaccharide might help to explain most of the compositional variations reported in the literature for Aloe vera carbohydrates.
The compound is also known by the United States Adopted Name (USAN) "acemannan," and by additional trade or experimental designations including Carrisyn, Carbopol-formulated acemannan gel, and processed Aloe vera gel (PAG). While the polysaccharides present in the inner gel, particularly acemannan, have been credited for many of the therapeutic effects of A. vera, other constituents such as lectins, alkaloids, anthraquinones, anthrones, chromones, coumarins, and polyphenols also contribute to its diverse benefits.
Aloe vera is a medicinal plant species of the genus Aloe with a long history of usage around the world. Accepted botanical synonyms include Aloe barbadensis Miller and Aloe vera (L.) Burm.f. The plant belongs to the family Asphodelaceae (formerly classified in Liliaceae). Characterized by wide utility and profound healing properties, Aloe barbadensis Miller, often referred to as the "real aloe," is a common component in skincare and health products.
A prominent feature of the Aloe vera filet is its high water content, ranging from 98.5% to 99.5% of fresh matter. More than 60% of the remaining solid matter is made up of polysaccharides. The acemannan is concentrated in the inner parenchymatous tissue—the clear gel or "filet"—that fills the interior of each mature leaf.
Aloe vera products are typically made from the gel. Aloe vera acemannan may be used in skin lotions, cosmetics, ointments, and gels for minor burns, skin abrasions, insect bites, and windburn.
In biomedical research and clinical dentistry, a more purified and specifically formulated range of delivery forms has been developed. In recent years, clinical treatment cases using acemannan as a biomaterial have emerged, especially in tissue regeneration. Considerable progress has been made in the preparation of acemannan in combination with other compounds to form composite hydrogels, aerogels, membranes, and scaffolds.
Acemannan has been processed into a freeze-dried sponge form and disinfected by UV irradiation. The acemannan powder is prepared in holders in 5% w/v of distilled water, then freeze-dried, and generated in sponge form in various dosage units (1 mg, 2 mg, 4 mg, 8 mg). The generated sponges were characterized using ¹³C-NMR, ¹H-NMR, FT-IR, and scanning electron microscopy.
Acemannan has also found many applications in the medical industry. An acemannan-rich sponge was more easily absorbed than a complex inorganic material, and can also act as a scaffold to provide migration and attachment of cell growth factors, because the sponge can effectively fix a blood clot in an orbit.
Oral dietary supplement products typically standardize acemannan content from the inner leaf gel; products may be presented as capsules, powders, beverages, or aloe juices. Many commercial aloe products do not list their acemannan content, and independent testing has found that some products contain little or no acemannan.
Aloe vera is native to hot climates and has been utilised medicinally by different cultures, including the Egyptian, Indian, Chinese, and European cultures for about five thousand years. The Ebers Papyrus, a 110-page scroll written circa 1550 BC, contains one of the earliest recorded references to the power of aloe vera, which was considered a "plant of immortality." Used as a traditional topical skin treatment and moisturizer, aloe vera is a fleshy succulent plant originally found in its native Arabian Peninsula but has since been spread and grown all over the planet.
Aloe vera was the traditional medicine of many cultures as an anthelmintic, cathartic, and stomachic, and was used for leprosy, burns, and allergic conditions. It has been used for the treatment of a variety of inflammatory digestive and skin ailments, including inflammatory bowel disease. A. vera has been used as a household remedy for burns for many centuries, and several recent studies have investigated its efficacy in greater depth.
Aloe arborescens Miller, a popular traditional remedy in Japan, is used to treat a broad spectrum of conditions, from digestive problems to athlete's foot.
It is important to note that traditional use was directed at the whole gel or whole-leaf preparation of Aloe vera. The isolation and specific characterization of acemannan as the principal bioactive polysaccharide is a modern scientific achievement, not a traditional distinction. The therapeutic effects historically attributed to aloe gel preparations are now, in many cases, attributed in part to acemannan by contemporary researchers, though acemannan itself was not identified as a distinct molecule until the latter twentieth century.
Acemannan is considered to be a natural polysaccharide with good biodegradability and biocompatibility extracted from Aloe vera and has a wide range of applications in the biomedical field due to excellent immunomodulatory, antiviral, antitumor, and tissue regeneration effects.
The distribution of acetyl groups and galactosyl units in the main chain can have a significant effect on the physical and biological characteristics of acemannan. Biological activity is known to depend on molecular weight, degree of acetylation, and the integrity of the long-chain polymer structure. In vitro outcomes demonstrate that the breakage of acemannan chains into smaller fragments enhances biological effects.
Acemannan primarily exerts its immunomodulatory properties by activating innate immune cells, specifically macrophages and dendritic cells. This activation leads to the production of various cytokines, such as IL-1, IL-6, IL-12, TNF-α, colony-stimulating factors (CSFs), and stem cell factors. Acemannan induces the release of IL-12, a cytokine that triggers the activation of natural killer cells and facilitates the proliferation and activation of T cells.
The presence of IL-1, IL-6, and TNF-α, released by macrophages and dendritic cells upon activation, can partially account for the wound-healing effects of acemannan, as the combined action of these cytokines promotes robust fibroblast proliferation. The enhanced phagocytic activity displayed by activated macrophages plays a role in facilitating the wound healing process. Moreover, the hematopoiesis-enhancing activity of acemannan can be attributed to the production of CSFs.
It has been found that acemannan can stimulate macrophage cytokine production, nitric oxide release, surface molecule expression, and cell morphologic changes. The production of the cytokines IL-6 and TNF-α is dependent on the dose of acemannan provided.
Research findings indicate that acemannan can regulate macrophage activation by targeting the PI3K/Akt/GSK-3β signaling pathway, enhancing macrophage M2 polarization and phagocytosis in RAW264.7 cells, thereby altering the phenotypic balance of macrophages.
In vitro fragments of acemannan can intravenously boost vaccine efficacy or entrain the immune system to attack cancer cells by mannose receptor agonism of macrophage or dendritic cells. In addition, acemannan enhances alloresponsiveness, increases phagocytosis, and increases natural killer cell activity of mixed lymphocyte cultures.
Processed aloe vera gel (PAG) rich in acemannan reduced the activation of nuclear factor kappa B (NF-κB) through the activation of peroxisome proliferator-activated receptor gamma, leading to the inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression. The expression and phosphorylation of signal transducer, activator of transcription 3, and cell cycle progression-inducing factors including cyclin-dependent kinase 4, cyclin D1, and ERK 1/2 were decreased by PAG, resulting in inhibition of colorectal cancer.
Acemannan accelerates cell proliferation and skin wound healing through the AKT/mTOR signaling pathway. Acemannan significantly accelerated skin wound closure and cell proliferation. Bone morphogenetic protein 2 (BMP-2) plays an important role in inducing new odontoblast formation and wound healing. It was proposed that acemannan could stimulate the expression of BMP-2 in pulpal and periodontal fibroblasts, which laid the foundation for the theory that acemannan promotes hard tissue regeneration.
In topical applications, an acemannan/chitosan combination accelerates the closure of wounds by promoting granular tissue formation, which creates a barrier between macrophages or neutrophils and the wound dressing. This causes M2 polarisation, reversal of inflammation, and acceleration of the re-epithelialisation process.
Kahlon et al. found that acemannan had a concentration-dependent inhibitory effect on the replication of HIV in CEM-SS cells infected with the HIV-1 RFII strain. After treating the infected cells with acemannan, the viral load, free virus, syncytium formation, and cytopathic effect were all reduced. Acemannan has also been shown to have in vitro activity against HIV-1, with the effect attributed to modification of the virus-mediated glycosylation process.
With oral consumption, epithelialisation occurs at injured sites in the small intestine or colon. The main advantage of dietary acemannan is the attenuation of the digestive process, increasing satiety, and slowing the release of sugars from starches. In the colon, acemannan is digested by microbes into short-chain fatty acids that are absorbed and augment the sensation of satiety and confer a host of other health benefits.
Acemannan is the name given to the major carbohydrate fraction obtained from the gel of the Aloe vera leaf. It has been claimed to have several important therapeutic properties including acceleration of wound healing, immune stimulation, anti-cancer and anti-viral effects. The biological mechanisms of these activities are not fully elucidated, but because of this wide diversity of effects, it is believed they may be exerted through pluripotent effector cells such as macrophages. The effects of acemannan on the mouse macrophage cell line RAW 264.7 cells were investigated. It was found that acemannan could stimulate macrophage cytokine production, nitric oxide release, surface molecule expression, and cell morphologic changes. The production of the cytokines IL-6 and TNF-α were dependent on the dose of acemannan provided. Nitric oxide production, cell morphologic changes, and surface antigen expression were increased in response to stimulation by a mixture of acemannan and IFN-γ.
Evidence strength: Immunomodulatory effects are well-documented in cell culture and animal models. Human clinical evidence for immune stimulation as a standalone, controlled clinical endpoint is limited, and large randomized controlled trials (RCTs) are lacking.
Acemannan is a complex water-soluble polymanno-galacto acetate derived from Aloe vera that was marketed as a wound-healing agent for the care of ulcers, burns, and postsurgical incisions.
Acemannan is a bioactive polysaccharide promoting tissue repair; however, the roles of acemannan in skin wound healing and the underlying molecular mechanisms are largely unclear. A mouse skin wound model and skin primary fibroblasts were used to demonstrate the positive effect of acemannan on cutaneous wound healing. The expressions of cell proliferation nuclear antigen ki-67, cyclin D1, and activity of AKT/mTOR signaling were analyzed in acemannan-treated fibroblasts and mice, with rapamycin and AKT inhibitor VIII used to determine the key role of AKT/mTOR signaling. Acemannan significantly accelerated skin wound closure and cell proliferation.
Histological analysis found that the wound edge of the acemannan-treated group was covered by epithelial cells, and the connective tissue layer showed relatively fewer inflammatory cells and more fibroblasts.
Evidence strength: Cutaneous wound healing evidence is primarily from in vitro and animal studies. Controlled human clinical trials specifically isolating acemannan (as opposed to whole aloe vera gel) in wound healing are limited.
Dentistry represents the area in which acemannan has the strongest body of peer-reviewed clinical evidence, including human trials.
A study investigated the effect of acemannan on dentin formation. Primary human dental pulp cells were treated with acemannan, and new DNA synthesis, bone morphogenetic protein-2 (BMP-2), alkaline phosphatase activity, dentin sialoprotein expression, and mineralization were determined by multiple assay methods. The upper first molars of 24 male Sprague Dawley rats were intentionally exposed and capped with either acemannan or calcium hydroxide. At day 28, acemannan significantly increased pulp cell proliferation, BMP-2, alkaline phosphatase activity, dentin sialoprotein expression, and mineralization compared with the untreated group.
Acemannan significantly increased pulp cell proliferation, alkaline phosphatase, type I collagen, BMP-2, BMP-4, vascular endothelial growth factor, and dentin sialoprotein expression and mineralization. Acemannan was found to be biocompatible with the dental pulp, and stimulated dentin regeneration in teeth with reversible pulpitis.
A non-inferiority clinical trial was conducted to compare the effectiveness of ProRoot MTA (mineral trioxide aggregate) and acemannan sponges as capping materials in partial pulpotomized immature permanent teeth. Patients aged 7–13 years (mean 9.2 ± 1.5 years) were recruited from the National Hospital of Odonto-stomatology, Hanoi, Vietnam between October 2015 and October 2017.
At 6 months, the overall clinical and radiographic success rates of direct pulp capping with acemannan and calcium hydroxide were 72.73% and 70.0%, respectively. The histopathological results indicated that the acemannan-treated group had significantly better histopathological responses compared with the calcium hydroxide-treated group (p < 0.05). These data suggest acemannan offers a valuable alternative biomaterial for vital pulp therapy in primary teeth.
A study was designed to elucidate the safety and effectiveness of acemannan in the treatment of oral aphthous ulceration. A skin patch test was performed on 100 healthy subjects, and 0.5% acemannan in Carbopol® 934P NF was applied to the oral mucosa of the lower lip of 50 healthy participants three times per day for 7 days. Oral examinations and blood tests measuring liver and kidney function were performed to assess side effects. Another 180 subjects with recurrent aphthous ulceration randomly received one of three treatments: 0.1% triamcinolone acetonide, 0.5% acemannan in Carbopol® 934P NF, or pure Carbopol® 934P NF, applied three times per day for 7 days. No subjects exhibited allergic reactions or side effects to acemannan.
Thirty-five female Sprague–Dawley rats were used in an in vivo study. Seven-mm diameter mid-calvarial defects were created and randomly allocated into blood clot control and acemannan groups (1 mg, 2 mg, 4 mg, and 8 mg). After four weeks, microcomputed tomography (microCT) revealed a significant increase in bone surface and bone volume in the 1 mg and 2 mg groups, and tissue mineral density in the 4 mg and 8 mg groups compared with the control group (p < 0.05). Histologically, the acemannan-treated groups had denser bone matrix compared with the control group. Acemannan was found to be an effective bioactive agent for bone regeneration, enhancing bone growth as assayed in two- and three-dimensions.
From an initial pool of 185 studies retrieved, a systematic review selected 16 eligible articles comprising nine experimental studies, four clinical trials, and two case reports/case series. The findings indicate that A. vera and acemannan promote osteogenic differentiation, reduce inflammation, and enhance bone healing, making them promising agents for dental and orthopedic applications. The review highlights the potential of acemannan and Aloe vera as effective biological agents in bone regeneration strategies.
In recent years, clinical case reports on the application of acemannan as a novel biomedical material in tissue regenerative medicine have emerged; it is mainly used in bone tissue engineering, pulp–dentin complex regeneration engineering, and soft tissue repair, among other operations.
Evidence strength: Dental and bone regeneration evidence is supported by multiple in vitro studies, animal trials, and a limited but growing number of controlled human clinical trials (primarily in pediatric and adolescent populations). Evidence is promising but not yet sufficient to establish acemannan as an established standard of care over existing materials such as mineral trioxide aggregate (MTA). Further large-scale RCTs are required.
In several in vivo and in vitro studies, acemannan has been shown to help treat the immunosuppressive symptoms of immunodeficiency virus infection. A series of in vitro experiments were conducted to evaluate the synergistic antiviral effects of acemannan in combination with azidothymidine (AZT) and acyclovir (ACY). Acemannan has been reported to have antiviral activity against herpes and measles viruses in viral plaque assays using VERO monolayers as target cells.
These mechanisms can account for the increase in absolute CD-4 (T-4) counts in HIV-infected patients as well as for the reduction in symptoms associated with concurrent infections. Physicians treating HIV-infected patients with acemannan have reported a highly significant reduction in HIV symptoms and other symptoms associated with concurrent infections. However, these observations derive from early-stage clinical pilot data and reports, not from large, placebo-controlled randomized trials.
Evidence strength: Antiviral evidence is predominantly preclinical (in vitro and animal). Early pilot human data from HIV-infected patients are limited by very small sample sizes and absence of contemporary trial design standards. Acemannan is not an approved antiviral drug.
It is believed that acemannan exerts its antitumor activity by activating the multipotent effector cells in the immune system, mainly macrophages, thereby stimulating the production of cytokines. Acemannan can activate macrophages to produce monokines, such as IL-1 and TNF, which stimulate blastogenesis in thymocytes and induce necrosis and the disappearance of Norman mouse sarcoma.
Acemannan exhibited macrophage-activating activity in ICR mice implanted with sarcoma 180 cells compared with an untreated group. Results confirm that the macrophage-activating activity of acemannan shown in vitro is correlated with the antitumor activity in vivo.
Studies have reported that acemannan can help treat colon cancer. By reducing the activation of nuclear factor kappa B (NF-κB), processed Aloe vera gel (PAG) rich in acemannan can inhibit inducible NO synthase and cyclooxygenase-2 expression.
Evidence strength: Anticancer evidence is limited to in vitro cell culture studies and animal models. No published, adequately powered clinical trials in human cancer patients have specifically examined acemannan as a primary anticancer therapy. Findings remain preliminary and should not be interpreted as therapeutic evidence in humans.
It has been reported that acemannan can be regarded as a potential prebiotic in protecting gastrointestinal health. In Gullón's study (2015), stimulation of acemannan fermentation was carried out using artificial intestinal microbiota made from stool samples of six healthy donors. The prebiotic activity was assessed by the quantification of short-chain fatty acids (SCFA) and the evaluation of dynamic bacterial population in mixed fecal cultures by fluorescence in situ hybridization. These findings support the idea that acemannan could be developed as a prebiotic to improve gastrointestinal health.
Evidence strength: Gastrointestinal and prebiotic evidence is principally from in vitro fermentation models and mechanistic studies. Clinical human data specific to acemannan (rather than whole aloe vera preparations) are sparse. The prebiotic potential is biologically plausible but unconfirmed in robust human trials.
Acemannan has a significant effect on the healing of alveolar bone and further promotes bone formation, suggesting that acemannan may be a natural biopolysaccharide material with anti-tumor activity and has received increasing scientific attention in recent years.
Marked healing with almost no residue in bone defect was observed in a group treated with the combination therapy of dental pulp stem cells and acemannan (8 mg/mL) in a rabbit mandibular model. Limitations of such studies include small sample sizes and short follow-up of clinical outcome. Future investigations on long-term efficiency and cost-effectiveness of dental pulp stem cells together with biomaterials for regenerative purposes are essential. Based on the limited clinical trials carried out for bone regeneration, they may not yet be recommended for clinical practice.
Reported dosages vary considerably by route of administration and clinical context. The following are dosages specifically reported in identified research sources:
No authoritative regulatory body (e.g., NIH ODS, EMA, WHO) has established an official Recommended Dietary Allowance (RDA) or Tolerable Upper Intake Level (UL) for acemannan as a dietary supplement as of the date of this article.
Until now there are no published controlled in vivo toxicology studies of Aloe vera in humans. In animal studies, Aloe vera-derived ingredients were not found to be toxic in acute oral studies using mice and rats.
Although Aloe vera has long been considered a safe functional food material that can be used orally and topically, on many occasions it has not been as safe as commonly thought. Reported adverse effects in humans and toxicity, genotoxicity, and carcinogenicity in both in vitro and in vivo studies raise questions as to whether the components in Aloe vera may have tumor-promoting activities in humans.
A critical safety distinction must be drawn between acemannan (derived from the inner gel) and aloe latex. Aloe vera latex or exudate is distributed within vascular bundles located between the plant's outer skin (rind) and the pulp. The pericyclic tubules store and transport Aloe vera latex along the margin of the leaf. The latex is yellow-brownish in color and has a bitter taste. The latex contains anthraquinone glycosides (aloins), which are the compounds primarily associated with cathartic and potentially genotoxic effects — not acemannan itself.
The most concerning safety data for aloe vera comes from animal toxicology studies: the National Toxicology Program (NTP) conducted two-year studies in rats and mice using non-decolorized whole leaf extract of aloe vera. These studies found clear evidence of carcinogenic activity, with increased incidence of tumors in the large intestine. Due to its widespread human exposure and concerns that some components may cause cancer, in 1998 the National Cancer Institute nominated Aloe vera as a high-priority candidate for a carcinogenicity study under the National Toxicology Program. These findings relate to non-decolorized whole leaf extract (which includes latex components) and are not specific to purified acemannan from the inner gel.
Oral ingestion of aloe vera extracts may cause acute abdominal pain and cramps, and hepatitis if consumed chronically. Several case reports on toxicity or hypersensitivity of aloe products in humans are available. In one case, a 35-year-old woman experienced massive intraoperative bleeding after oral consumption of Aloe vera tablets for two weeks before surgery. Compounds contained within Aloe vera can reduce the synthesis of prostaglandin, thus inhibiting secondary aggregation of platelets. These hepatotoxicity and coagulation-related reports involve whole-leaf or latex-containing preparations; specific implication of acemannan as the causative agent has not been established.
Overuse of aloe latex may increase the risk of adverse effects from cardiac glycosides, such as digoxin, which are used for some heart problems. This interaction is attributed to the laxative effect of aloe latex causing electrolyte depletion (particularly potassium loss), which can potentiate cardiac glycoside toxicity — not to acemannan specifically.
Aloe—in gel, latex, or whole leaf extract form—when taken by mouth may be unsafe during pregnancy and while breastfeeding. It should not be used during pregnancy.
Some people have allergic reactions to aloe when used on skin. In the clinical acemannan aphthous ulcer study (n=180), no subjects exhibited allergic reactions or side effects to acemannan.
Many commercial aloe products do not list their acemannan content, and independent testing has found that some products contain little or no acemannan. This raises important questions about the applicability of research findings to consumer products and the comparability of commercial preparations with materials used in clinical studies.
In pilot studies, administration of acemannan to dogs caused an absolute monocytosis in blood samples taken for complete white blood cell counts and morphology differential. Within 2 hours after oral administration of high doses of acemannan, large activated monocytes appeared in circulation. A similar effect has been observed in humans. This is consistent with acemannan's known mechanism of macrophage activation, though the clinical significance of transient monocytosis has not been characterized in controlled human studies.
Even though the plant is a promising herb with various clinical applications in medicine and dentistry, more clinical research needs to be undertaken to validate and explain the action of acemannan in healing, so that it can be established in the field of medicine. A more precise understanding of the biological activities is required to develop Aloe vera as a pharmaceutical source.
The majority of evidence for acemannan's purported therapeutic properties derives from in vitro cell culture experiments and animal models. In the dental and oral medicine domain, a meaningful number of controlled clinical trials exist, representing the most rigorous human evidence base for the compound. Immunomodulatory, antiviral, antitumor, and gastrointestinal human clinical data remain preliminary. The field is further complicated by the variability in acemannan content and molecular weight between commercial preparations, the sensitivity of the polysaccharide structure to processing and heat, and the lack of standardized dosing protocols across studies.
Condiciones de salud que Acemannan puede ayudar a apoyar.
Acemannan exhibits direct radical-scavenging activity, with DPPH assays demonstrating 45% radical clearance and protective effects against H₂O₂-induced oxidative cell damage. Acetylated polysaccharides like acemannan also enhance superoxide radical clearance and total antioxidant capacity relative to native polysaccharides.
Acemannan stimulates osteoblastic differentiation markers (BMP-2, RUNX2, ALP, COL1) and promotes alveolar bone, cementum, and periodontal ligament regeneration. Clinical trials in dental contexts show enhanced bone dimensional stability. Evidence is focused on alveolar/craniofacial bone rather than systemic bone density.
Acemannan is the principal bioactive polysaccharide from Aloe vera gel, responsible for much of its wound-healing activity in burns. Preclinical studies show acemannan activates macrophages, accelerates wound contraction, and promotes re-epithelialization in burn wound models. It is specifically identified as a key constituent mediating aloe vera's documented burn-healing effects in clinical research.
Acemannan, a polysaccharide extracted from Aloe vera, has been studied in randomized controlled trials for recurrent aphthous stomatitis (RAS). In an RCT by Bhalang et al. (2013, J Altern Complement Med), acemannan demonstrated significant pain relief and ulcer reduction compared to placebo, though corticosteroids remained more effective. Its mechanisms include immunomodulation, promotion of fibroblast proliferation, and stimulation of keratinocyte growth factors that facilitate mucosal healing.
Acemannan modulates macrophage polarization, suppressing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. In vitro and animal studies demonstrate consistent anti-inflammatory activity via TLR-4/TLR-5 receptor activation and promotion of M2 macrophage phenotypes. Human clinical data remain indirect (via whole Aloe vera preparations), but mechanistic evidence is well-characterized.
Acemannan, the principal sulfated polysaccharide of Aloe vera, demonstrates direct inhibitory effects against HSV-1 in vitro by interfering with viral attachment to host cell glycosaminoglycans. It also promotes wound healing via fibroblast stimulation. It is considered the primary bioactive contributing to aloe vera's documented anti-HSV activity.
Acemannan has been investigated in a pilot clinical study for inflammatory bowel disease including ulcerative colitis, with all participants showing score improvements. Aloe vera gel (the major vehicle of acemannan) showed benefit in a double-blind, placebo-controlled trial for active ulcerative colitis. Mechanistic support comes from rodent models of colitis.
Acemannan upregulates type I collagen and glycosaminoglycan (GAG) synthesis and stimulates fibroblast proliferation, directly supporting extracellular matrix integrity. These effects have been demonstrated in gingival, skin, and periodontal connective tissues in both in vitro and in vivo models.
Acemannan is the primary bioactive polysaccharide from Aloe vera gel, acting as a humectant and water-retaining agent in the stratum corneum. It is responsible for the moisture-binding activity of aloe gel and supports skin barrier function. Evidence from aquaporin-3 upregulation studies and clinical aloe research directly implicates acemannan in dry skin improvement.
Acemannan stimulates gingival fibroblast proliferation, KGF-1, VEGF, and type I collagen expression, supporting periodontal tissue regeneration. Clinical trials show it enhances dimensional bone stability in guided bone regeneration, and case reports document improved clinical parameters and radiographic bone fill over 5 years.
Acemannan functions as a prebiotic substrate: it is fermented by colonic microbiota into short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. In vitro studies using human fecal cultures show selective stimulation of beneficial bacteria. This activity underpins its documented GI health effects.
Acemannan has been evaluated in exploratory clinical pilot work for IBD (Crohn's disease and ulcerative colitis), showing improvement in all enrolled patients. It also exerts prebiotic and mucosal-healing effects relevant to IBD pathophysiology. Whole Aloe vera gel (acemannan-containing) has shown benefit in a placebo-controlled UC trial.
Acemannan is the primary bioactive polysaccharide (beta-1,4-acemannan) from Aloe vera inner leaf gel, documented to enhance gut-barrier repair by upregulating ZO-1 tight junction proteins and promoting mucosal regeneration. A ScienceDirect study showed aloe vera glucomannan (closely related polysaccharide) maintains intestinal barrier integrity via the Nrf2-mitochondria axis. Acemannan also has documented immunomodulatory effects relevant to intestinal mucosal immune function.
Acemannan-loaded nanogel formulations have shown significant reductions in psoriasis-like skin inflammation in animal models, reducing erythema, scaling, and pro-inflammatory cytokines. Clinical studies with Aloe vera gel (acemannan-containing) have shown improvements in plaque psoriasis, and a systematic review supports the benefit of topical Aloe vera in psoriasis.
Acemannan, a polysaccharide from Aloe vera inner gel, has been studied for wound healing and scar modulation. In vitro and animal studies demonstrate it stimulates fibroblast proliferation, enhances collagen deposition, and reduces inflammatory cytokines. Human clinical trials specifically on scar tissue are limited but early findings are supportive.
Acemannan promotes fibroblast proliferation and type I collagen synthesis in vitro and in wound healing models. Clinical studies using acemannan-enriched Aloe vera gel preparations have demonstrated accelerated wound closure, improved skin elasticity, and enhanced collagen deposition. A human study in women over 45 found improved skin elasticity and collagen within 90 days of oral Aloe vera gel.
Acemannan accelerates healing of oral aphthous ulcers and has demonstrated efficacy in pressure ulcer management in small clinical studies. It stimulates fibroblast proliferation, epithelial growth factors, and collagen synthesis. Animal data support gastrointestinal ulcer healing as well.
Acemannan has demonstrated in vitro and in vivo antiviral activity against HIV-1, influenza, and measles viruses, attributed to inhibition of viral replication and immunostimulation. A small human clinical study in AIDS patients showed clinical improvement over 900 days at 800 mg/day orally.
Acemannan is the primary bioactive polysaccharide from Aloe vera gel. It has been shown in multiple studies to stimulate macrophage activation, promote fibroblast proliferation, and accelerate wound closure. Clinical and preclinical studies support its use in dental, skin, and burn wound healing.
Acemannan is the primary bioactive polysaccharide from Aloe vera used traditionally and in emerging clinical research for wound healing and post-surgical tissue repair. It stimulates macrophage activation, fibroblast proliferation, and cytokine production relevant to post-surgical healing.
Sistemas corporales que Acemannan puede ayudar a apoyar.
Volver